Acetylcysteine/pentoxifylline

Drug Profile

Acetylcysteine/pentoxifylline

Alternative Names: Acetylcysteine/oxpentifylline; Oxpentifylline/acetylcysteine; Pentoxifylline/acetylcysteine; PTL-202

Latest Information Update: 27 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pacific Therapeutics
  • Class Antifibrotics; Reducing agents; Small molecules; Sulfur amino acids; Xanthines
  • Mechanism of Action Antioxidants; Cytokine inhibitors; Free radical scavengers; Phosphoric diester hydrolase inhibitors; Platelet aggregation inhibitors; Transforming growth factor beta inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 08 May 2014 Acetylcysteine/pentoxifylline is still in phase I trials for Pulmonary fibrosis
  • 04 Feb 2014 Pacific Therapeutics terminates its technology licence with Dalhousie University in Canada
  • 22 Aug 2012 Phase-I clinical trials in volunteers in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top